Program
LY4065967
A development code. Also written as “LY4065967 ISA”, “LY4065967 Tablet” and “LY4065967 Formulated Capsule”.
In Eli Lilly's pipeline, AT2R antagonist
. Its studies are mostly in Osteoarthritis, Knee · Neuralgia · Chronic Pain, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 74 open or running | phase 2since Aug 1, 2023 | Aug 1, 2023 | Apr 2027phase 2 · NCT05986292 |
- Named in Eli Lilly’s own pipeline as
AT2R Antagonist
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 1, 2023First study: phase 2 study in Osteoarthritis, KneeFirst studyNCT05986292 · 10,000 planned · United States, Puerto Rico
- Sep 10, 2024Phase 1 study in HealthyNCT06594159 · 59 enrolled · Japan
- Jun 19, 2025Phase 1 study in HealthyNCT07039045 · 16 enrolled · United States
- Dec 9, 2025Phase 2 study in Diabetic Peripheral Neuropathic PainNCT07285018 · 150 planned · United States, Puerto Rico
- May 19, 2026Phase 1 study in HealthyNCT07607483 · 36 enrolled · United States
- Jun 8, 20262 phase 2 studiesNCT07641517, NCT07641504
Ahead
- Apr 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT07641517
- Apr 2027Primary completion: phase 2 study in Chronic PainNCT07641504
- Apr 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT05986292
- Jul 2027Primary completion: phase 2 study in Diabetic Peripheral Neuropathic PainNCT07285018
TargetBeta
“AT2R antagonist”the company's pipeline, read by Claude · source
Other programs on AGTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TRD205 | Sino Biopharmaceutical | phase 2 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07641517Osteoarthritis, Knee · United States, Puerto Rico | 2 | Recruiting | Apr 2027 | 150 |
| NCT07641504Chronic Pain · United States, Puerto Rico | 2 | Recruiting | Apr 2027 | 150 |
| NCT07607483Healthy · United States | 1 | Completed | Jul 27, 2026 | 36 |
| NCT07285018Diabetic Peripheral Neuropathic Pain · United States, Puerto Rico | 2 | Recruiting | Jul 2027 | 150 |
| NCT07039045Healthy · United States | 1 | Completed | Aug 16, 2025 | 16 |
| NCT06594159Healthy · Japan | 1 | Completed | Mar 11, 2025 | 59 |
| NCT05986292Osteoarthritis, Knee · United States, Puerto Rico | 2 | Recruiting | Apr 2027 | 10,000 |
How it is read
Names in the registry
- “LY4065967”, 5 entries
- “LY4065967 ISA”, 1 entry
- “LY4065967 Tablet”, 1 entry
- “LY4065967 Formulated Capsule”, 1 entry
- “LY4065967 Capsule”, 1 entry
Codes read as this program: LY4065967.
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 2 studies
- Neuralgia, 1 study
- Chronic Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.